Dizal Announces New Data from the Phase I/II Study of Golidocitnib in Refractory or Relapsed Peripheral T Cell Lymphoma Selected for Oral Presentation at 2022 EHA Annual Meeting

/PRNewswire/ -- Dizal (SSE: 688192) will present the data from an ongoing phase I/II study of golidocitnib, a selective JAK1 inhibitor, in refractory or...

Related Keywords

Austria ,Shanghai ,China ,Vienna ,Wien ,Seog Kim ,Xiaolin Zhang ,International Conference On Malignant Lymphoma ,Samsung Medical Center ,European Hematology Association ,Business Development ,Hybrid Congress ,Track Designation ,Malignant Lymphoma ,Chief Executive Officer ,Fast Track ,Aggressive Lymphoma ,Abstract Code ,Won Seog Kim ,Samsung Medical ,Dizal Pharmaceutical ,